On 2 July 2024 the President of the Agency for Health Technology Assessment and Tariff System issued the following recommendation No. 65/2024 on the evaluation of the drug Zynlonta (loncastuximab tesirine) within the framework of the drug program “Treatment of patients with B-cell lymphoma (ICD-10: C82, C83, C85)”